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ABSTRACT 
The present research work discusses the development of UV-spectrophotometric method for estimation of Naproxen. Simple, specific, accurate 
and cost effective spectrophotometric method has been developed for estimation of naproxen sodium in bulk as well as formulation. The 
optimum conditions for the analysis of the drug were established. The maximum wavelength (λmax) was found to be 331 nm. The validation was 
performed as per ICH guidelines for linearity, accuracy, precision, LOD and LOQ. The linearity was found in the concentration range of 3-24 µg / 
ml for Zero, first and second order derivative spectroscopy. The correlation coefficients were found to be 0.9997, 0.9999 and 0.9998, 
respectively. The obtained (r2) values show that the selected concentration range gives good linearity. All calibration curves show a linear 
relationship between the absorbance and concentration with coefficient of correlation 0.999. The regression of curve was Y = 0.0372 x - 0.0038. 
The precision of method was found to be good. The results were within the range of 99.15 ± 0.14 – 101.38 ± 0.17 and were found to be highly 
accurate. The proposed method will be suitable for analysis of naproxen in bulk as well as pharmaceutical formulations in quality control 
purpose. It is thus concluded that the proposed method is new, simple, cost-effective, safe, accurate, precise and environmental friendly 
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INTRODUCTION 
Drug delivery through oral route is the most common and 
preferred route of drug administration both for solid and 
liquid dosage forms. However, solid dosage forms are 
popular because of the ease of administration, accurate 
dosage, self-medication, pain avoidance, and most 
importantly the patient compliance. Tablets and capsules are 
the most popular solid dosage forms. However, many people 
face difficulty in swallowing tablets and hard gelatin 
capsules. Orodispersible tablets are also called as orally 
disintegrating tablets, mouth-dissolving tablets, rapid-
dissolving tablets, fast-disintegrating tablets, fast-dissolving 
tablets. Recently, European Pharmacopoeia has used the 
term orodispersible tablets. This may be defined as uncoated 
tablets intended to be placed in the mouth where they 
disperse readily within 3 min before swallowing1. United 
States Pharmacopoeia has also approved these dosage forms 
as orodispersible tablets. Thus, orodispersible tablets are 
solid unit dosage forms like conventional tablets, but are 
composed of super disintegrants, which help them to 
dissolve the tablets within a minute in the mouth in the 
presence of saliva without any difficulty of swallowing2. It 
offers several advantages with respect to its stability, 
administration without water, accurate dosing, easy 
manufacturing, small packaging size, and handling. Due to 
the presence of super disintegrants, it gets dissolved quickly, 
resulting in rapid absorption of drug which in turn provides 
rapid onset of action. Since the absorption is taking place 
directly from the mouth, so, bioavailability of the drug 
increases. Drugs present in orodispersible tablets are also 
not suffering from first pass metabolism. Naproxen is 
chemically 2-(6-methoxynaphthalen-2-yl) propanoic acid3,4. 
It is used in the treatment of Inflammations, rheumatoid 
arthritis, musculoskeletal disorders and gout1. Naproxen is a 
non-steroidal anti-inflammatory drug (NSAID) commonly 
used for the reduction of moderate to severe pain, fever, 
inflammation and stiffness5. It works by inhibiting both the 
COX-1 and COX-2 enzymes. Literature review revealed that 
some spectrophotometric and HPLC methods have been 
reported for the estimation of naproxen in tablet 
formulation6 raw material, plasma 7, urine and intestinal 
perfusion samples. Since the nonspecific titrimetric assay 
method was specified for Naproxen API in the 
pharmacopoeia, hence, there was a need to develop a specific 
method which became the purpose of the further study. The 
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objective of the present work was to develop a simple, 
sensitive, precise and accurate UV spectrophotometric 
method for the determination of naproxen in bulk and 
semisolid formulations as per ICH Guidelines 8. 
Table 1: Chemicals and reagents 
S.No Materials Sources 
1. Naproxen Ajanta Ltd Mumbai 
2. Camphor Brucell Pvt.Ltd. Sagar 
3. Aspartame Hi-Media Mumbai 
4. Cross Carmellose Sodium Hi-Media Mumbai 
5. Sodium Starch Glycolate Hi-Media Mumbai 
6. Colloidal Silicon Dioxide Hi-Media Mumbai 
           7. Mannitol Hi-Media Mumbai 
 
Table 2: Instruments and apparatus 
S.No EQUIPMENT MODEL/COMPANY 
1. UV visible spectrophotometer  Model – 1372 Make ET (Double Beam) 
2.  FT IR spectrophotometer  IR Affinity- 1, Shimadzu 
3.  Electronic Weighing machine  DS-852 J Series Essae 
4.  Melting point apparatus  Microcontroller based melting point Apparatus 
5.  Tablet compression machine  Single punching machine 
6.  Hardness Tester  Monsanto hardness tester 
7.  Friability Test Apparatus  Roche Friabilator 
8  Tablet Disintegration Tester  Model – 911 Make – E 1 
9.  Tablet Dissolution Tester  6 Station programmable Model - TDT - 06L 
 Make – Electro lab. 
 
METHODS 
Identification and Characterization of Naproxen 
Identification 
FTIR spectrum of Naproxen 
FTIR spectrum- In the preparation of Orodispersible tablet, 
drug and Excipient may interact as they are in close contact 
with each other, which could lead to the instability of drug, 
Preformulation studies regarding the drug-excipient 
interaction are therefore very critical in selecting 
appropriate excipients. FT-IR spectroscopy was employed to 
ascertain the compatibility Naproxen and the selected 
excipients. The pure drugs and the drug with excipients were 
scanned separately and results are shown in (Fig: 1) 
Physiochemical Characteristics 
Melting Point-M.P. of the Naproxen was found to be 152-
155°C at room temperature. 
Solubility- Solubility of Naproxen was shown in (Table No. 2)  
Formulation 
Preparation of Orodispersible tablets by Direct 
Compression Technique: 
The term direct compression is used to define the 
process by which tablets are compressed directly from the 
powder blends of active ingredients and suitable excipients, 
which will flow uniformly in the die cavity and forms a film 
contact. In this method, addition of super-disintegrants in 
optimum concentrations so as to achieve rapid 
disintegration with good mouth feels. Super disintegrants 
likes sodium starch gylcolate, cross povidone, cross 
carmellose sodium etc. Powders of drugs were 
mixed/blended with camphor as subliming agent and 
aspartame as quickly dissolvable sugar based excipients and 
Mannitol as Diluents, Cross Carmellose Sodium and Sodium 
Starch Glycolate as super-disintegrants9. All ingredients 
were passed through mesh # 60. Then 100mg of Naproxen 
were compressed on tablet punching machine to get tablets, 
each weighing 367.5mg. 
 
Table 3: Composition of Orodispersible tablets in (mg) 
Ingredients Fl F2 F3 F4 F5 
 Naproxen 100 100 100 100 100 
 Comphore - - 2.5 12.5 25 
 Aspartame 2.5 2.5 - 2.5 - 
 Cross Carmellose Sodium - 15 - 15 - 
 Sodium Starch Glycolate 15 - 15 - 15 
 Colloidal Silicon Dioxide - - - - 2.5 
 Mannitol 250 250 250 250 250 
 Total 367.5 - 
 
-  -  -  
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Evaluation of Tablets 
Preformulation studies: 
1. Bulk Density and Tapped Density - Both loose bulk 
density (LBD) and tapped bulk density (TBD) were 
determined. The accurately weighed amount sample taken in 
50 ml measuring cylinder of borosil measured/recorded the 
volume of packing and tapped 50 times on plane surface and 
tapped volume of packing recorded and LBD and TBD 
calculated by following formula. 
LBD = Mass of powder 
 Volume of packing 
TBD = Mass of powder 
 Tapped volume of packing 
2. Angle of repose- The frictional forces in loose powder or 
granules can be measured by the angle of repose. This is the 
maximum angle possible between the surface of a pile of 
powders or granules and the horizontal plane. 
       tan = h/r 
      θ = tan-1 (h/r) 
         Where, tan = angle of repose 
               h = Height 
                         r =  radius 
The granules were allowed to flow through the funnel fixed 
to a stand at definite height. The angle of repose was then 
calculated by measuring the height and radius of the heap of 
granules formed. 
 
Table 4: Relation between Angle of repose (θ) and flow 
property. 
Angle of Repose (θ) Flow property 
< 25 Excellent 
25-30 Good 
30-40 Passable 
>40 Very poor 
 
3. Percentage Compressibility 
Percentage compressibility of powder mix was determined 
by Carr's compressibility index calculated by following 
formula. 
Carr’s index % =  TBD - LBD x 100  
TBD 
Where, LBD = loose bulk density 
TBD = Tapped bulk density 
Table 5: Grading of the powders for their flow properties 
according to Carr's index 
Carr’s Index % Flow 
5-15 Excellent 
12-16 Good 
18-21 Fair to Possible 
23-25 Poor 
33-38 Very Poor 
>40 Very-Very Poor 
 
 
Post Compression Parameters: 
1. Physical appearance- All the prepared tablets were 
visually inspected for color, size and smoothness. 
2. Thickness uniformity- The aim of the present study was 
to check the uniformity of thickness of the formulated 
tablets. The thickness of the tablets was measured at 3 
different points using a digital caliper and average thickness 
of three readings was calculated. It is expressed in mm. 
3. Weight Uniformity- For weight variation test, 10 tablets 
from each formulation was weighed individually and the 
average weight was calculated. The US pharmacopoeia 
allows a little variation in the weight of the tablet. 
Table 6: Criteria for percentage deviation in weight 
variation 
Average Weight of 
Tablet 
Percentage 
Deviation 
130 mg or less 10 
More than 130 mg and  
less than 324 mg 
7.5 
324 and more 5 
 
4. Hardness- 
Hardness indicates the ability of a tablet to withstand 
mechanical shocks while handling. The hardness of the 
tablets was determined using Monsanto Hardness Tester. It 
is expressed in kg/cm2. Three tablets were randomly picked 
and hardness of the same tablets from each formulation was 
determined. The mean and standard deviation values were 
also calculated. 
5. Friability studies- 
Friability test is performed to assess the effect of friction and 
shocks, which may often cause tablet to chip, cap or break. 
Roche Friabilator was used for the purpose. Pre weighed 
sample of ten tablets were placed in the Friabilator, which 
was then operated for 100 revolutions. After 100 revolutions 
the tablets were dusted and reweighed. Compressed tablets 
should not lose more than 1% of their weight. 
Percentage Friability = (initial weight – final weight / initial 
weight) x 100 
6. Disintegration studies- 
In vitro disintegration time was performed by disintegration 
Apparatus at 50 rpm. 1000ml (water) was used as 
disintegration medium, the temperature of which was 
maintained at 37 ± 2°C and the time taken for complete 
disintegration of the tablet with no mass remaining in the 
apparatus was measured in seconds. 
7 .Wetting time- 
A piece of tissue paper (12 cm × 10.75 cm) folded twice was 
placed in a Petri dish (Internal Diameter = 9 cm) containing 9 
m of buffer solution simulating saliva pH 7.4. A tablet was 
placed on the paper and the time taken for complete wetting 
was noted. Three tablets from each formulation were 
randomly selected and the average wetting time was noted. 
8. In Vitro Dispersion Time- 
In vitro dispersion time was measured by dropping a tablet 
in a 10 ml measuring cylinder containing 6 ml of buffer 
solution simulating saliva fluid with reference to Indian 
pharmacopoeial standard (pH 7.4). 
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For UV  
Reagents and chemicals analytically pure Naproxen Jawa 
Pharmaceuticals (P) Ltd were available from Oasis 
Laboratories Jaipur, India. Double distilled water for 
analytical purpose was obtained from Milli-QR-O system. 
Naproxen was determined spectrophotometrically in bulk 
and marketed formulation by using 2M hydrochloric acid 
and 550µg/ml of potassium bromide-bromate as a strong 
oxidizing agent.  
Preparation of standard stock solution of Naproxen: 
Standard stock solution prepared by accurately weighing 
100 mg of Naproxen in 100 ml calibrated volumetric flask 
and made up the volume with distilled ethanol up to 100 ml. 
Preparation of the working standard stock solution: From 
the above standard stock solution A 10ml was pipetted using 
a 10ml volumetric pipette. This pipette solution was 
transferred carefully to another 100ml volumetric flask and 
dissolved further with distilled ethanol up to the 100ml mark 
to obtain a 100µg/ml solution (Stock solution B).  
Preparation of standard solution for calibration- Plots 
Weigh accurately about 100 mg of Naproxen and 100 mg 
transfer it to a 100 ml volumetric flask. Add 50 ml of 
methanol, sonicate it for 5 min to dissolve the content and 
make up the volume with methanol to give a concentration 
of 1000 μgmL-1 of Naproxen Stock solution was further 
diluted to give concentration of 100 μgmL-1 of Naproxen . 
Stock solution was diluted with methanol to give working 
standard solution containing 10 μgmL-1 of Naproxen. These 
solutions were scanned in the UV region of 200-400nm in 
1cm cell against methanol as a blank and the overlain spectra 
was recorded. 
Methodology 
 
• Method A: Zero Order Derivative Spectroscopy 
• Method B: First Order Derivative Spectroscopy 
• Method C: Second Order Derivative Spectroscopy
 
 
RESULT AND DISCUSSIONS 
 
Figure 1: Result of FTIR Spectra of Naproxen 
 
Table 7: Interpretation of FTIR of Naproxen 
S.No. Functional Groups Peak Wave 
No. cm-1 
1 C=O Streching 1726 
2 O-H Streching 3200 
3 O-H Bend 1419 
4 O-H Streching 1720 
5 O-H Bend 1018 
6 C=O Streching 1720 
  
Table 8: Solubility profile for Naproxen  
S.No. Solvent Result 
1 Methanol Soluble 
2 Ethanol Insoluble 
3 Water Soluble 
4 Acetone Insoluble 
5 Ether Insoluble  
 
Mandloi et al                                                                                                             Journal of Drug Delivery & Therapeutics. 2018; 8(6-A):33-42  
ISSN: 2250-1177                                                                                  [37]                                                                                 CODEN (USA): JDDTAO 
6.3.-Preparation of Orodispersible tablets – 
Table 9: Pre-compression Parameter of Orodispersible tablets 
S.No. Pre-compression studies Formulation 
F1 F2 F3 F4 F5 
1. Angle of repose(θ) 40.69o 30.26o 28-22o 25.56o 20.09o 
2. Bulk Density (g/ml) 0.78 0.82 0.73 0.75 0.70 
3. Tap Density (g/ml) 0.95 0.94 0.92 0.90 0.82 
4. Compressibility index (%) 9.8 7.3 5.8 9.0 6.9 
5. Hausners ratio 0.86 0.85 0.83 0.87 0.75 
 
Table 10: Post-Compression Parameter of Orodispersible tablets 
S.No. Pre-compression studies Formulation 
F1 F2 F3 F4 F5 
1 Uniformity of thickness (n=3) mm 5.3+0.33 5.6+0.78 5.4+0.77 5.6+0.78 5.5+0.78 
2 Hardness(n=3) kg/cm2 2.0+0.33 1.5+0.40 1.6+0.42 1.0+0.57 1.0+0.57 
3 Friability %(n=6) 1.16 0.24 0.20 0.22 0.10 
4 Weight Variation (n=10) 449+2.12 450+2.12 453+2.12 443+2.10 444+2.10 
5 Drug content in (mg) (n=3) 98.55±0.2 99.55±2.2 98.65±3.2 98.47±1.2 97.4±1.32 
6 Disintegration on tine in sec. at 37o 
C(n=3) 
46 48 45 46 53 
7 Wetting time in sec (n=3) 75+2.4 45+2.2 35+1.5 25+1.3 15+1.2 
8 In-vitro Dispersion time (sec) 150 115 90 75 45 
 
6.4. Result of Analysis of Orodispersible Tablet Formulation – 
Table 11: Assay of Orodispersible Tablet Formulation 
Formulation NAPROXEN 
Lable Claim (mg) %Purity 
F5 100 98.78 
 
   Method A: Zero Order Derivative Spectroscopy 
 
 Figure 2: Zero order spectra of Naproxen at 331nm 
Table 12: Results of calibration curve at 331 nm for Naproxen by Zero order Spectroscopy 
S. No. Conc. (µg/ml) Absorbance at 253 nm 
1  0  0  
2  3  0.112  
3  6  0.221  
4  9  0.328  
5  12  0.438  
6  15  0.458  
7  18  0.662  
8  21  0.779  
9  24  0.90  
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Table 13: Optimum conditions, Optical characteristics and Statistical data of the Regression equation in Zero order 
Spectroscopy 
Parameter  UV method  
λ max (nm)  331 
Beer’s law limits (µg / ml)  3-24  
Molar  extinction  coefficient (L mol-1 cm-1)  0.03653 X104  
Sandell’s sensitivity  
(µg / cm2-0.001 absorbance units)  
 0.02737  
Regression equation (Y*)  Y = 0.0372 x - 0.0038  
Slope (b)  0.0372  
Intercept (a)  -0.0038  
Correlation coefficient (r2)  0.9997  
Intraday Precision (% RSD**)  
Interday Precision (% RSD**)  
0.342  
                    0.395  
Limit of detection (µg / ml)  0.107  
Limit of quantitation (µg / ml)  0.325  
        *Y =  bx + a where x is the concentration of Naproxen in µg / ml and Y is the absorbance at the respective λ max.  
        **Average of Six determinations.  
Table: 14. Determination of Accuracy results for Naproxen at 331nm by Zero order Spectroscopy   
Brand used  Amount  
of sample  
(µg / ml)  
Amount of drug 
added  
(µg / ml)  
Amount 
Recovered  
% Recovery ±  
SD**  
Aleve  
10  7.5  7.46  99.46 ± 0.012  
10  15  15.23  101.53 ± 0.042  
10  22.5  22.25  98.85 ± 0.021  
Naprosyn  
20  7.5  7.56  100.80 ± 0.014  
20  15  14.92  99.46 ±0.037  
20  22.5  22.46  99.89 ± 0.028  
**Average of six determinations. 
Table: 15- Determination of Precision results for Naproxen at 331 nm by Zero order Spectroscopy 
Conc.     (µg / 
ml)  
Inter-day  
Absorbance  
Mean ± SD**  
% CV  
Intra-day  
Absorbance  
Mean ± SD**  
% CV  
3  0.1120 ± 0.001414  1.26  0.1135 ± 0.001871  1.64  
6  0.2231 ± 0.002639  1.18  0.2241 ± 0.002229  0.99  
9  0.3273 ± 0.001633  0.49  0.3255 ± 0.001872  0.57  
12  0.4371 ± 0.001472  0.33  0.4366 ± 0.001633  0.42  
15  0.5463 ± 0.00216  0.39  0.5451 ± 0.001472  0.34  
18     0.6625 ± 0.001871  0.28  0.6643 ± 0.001751  0.28  
21     0.7758 ±  0.002317  0.29  0.7761 ± 0.001941  0.25  
24     0.9110 ± 0.005657  0.62  0.9128 ± 0.006795  0.74  
         **Average of Six determinations  
 
 
Figure 3: Linearity curve for Naproxen at 331 nm by Zero order Spectroscopy 
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Table: 16: Ruggedness results for Naproxen at 331 nm by Zero order Spectroscopy 
Brand used  Label 
claim  
(mg/ml)  
Analyst I  Analyst II  
Amount found** 
(mg/ml) 
% Recovery ± 
SD** 
 
Amount found** 
(mg/ml) 
% Recovery ± 
SD** 
 
Aleve  20  20.28  101.42 ± 0.0170  19.34  99.67 ± 0.0294  
Naprosyn 20  20.14  101.04 ± 0.0294  19.97  99.07 ± 0.0281  
**Average of six determinations. 
 
Method B:  First Order Derivative Spectroscopy 
 
Figure 4: First order derivative spectra of Naproxen at 310 nm  
 
Table: 17: Results of calibration curve at 310 nm for Naproxen by First order derivative Spectroscopy 
Sl. no.  Conc. (µg / ml)   Absorbance  
1  0  0  
2  3  0.043  
3  6  0.089  
4  9  0.137  
5  12  0.188  
6  15  0.232  
7  18  0.275  
8  21  0.322  
9  24  0.368  
 
Table : 18- Optimum conditions, Optical characteristics and Statistical data of the Regression equation in First order 
derivative Spectroscopy   
Parameter  UV method  
λ max (nm)  310 
Beer’s law limits (µg / ml)  3-24  
Molar extinction coefficient (L mol-1 cm-1)  0.0154 X104  
Sandell’s sensitivity  
(µg / cm2 - 0.001 absorbance units)   
0.0646  
Regression equation (Y*)  Y = 0.0154 x - 0.0018  
Slope (b)  0.0154  
Intercept (a)  -0.0018  
Correlation coefficient(r2)  0.9999  
Intraday Precision (% RSD**)  
Interday Precision (% RSD**)  
0.842  
0.885  
Limit of detection (µg / ml)  0.146  
Limit of quantitation (µg / ml)  0.442  
          *Y =  bx + a where x is the concentration of Naproxen in µg / ml and Y is the absorbance at the respective λ max.  
         **Average of Six determinations.  
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Table: 19. Determination of Accuracy results for Naproxen by First order derivative Spectroscopy  
Brand used  Amount  
of sample  
(µg / ml)  
Amount of 
drug added  
(µg / ml)  
Amount 
Recovered  
% Recovery ±  
SD**  
Aleve 
15  12  12.21  101.75 ± 0.030  
15  15  14.93  99.53 ± 0.045  
15  18  18.24  101.33 ± 0.027   
Naprosyn 
12  12  11.92  99.33 ± 0.034  
12  15  15.31  102.06 ± 0.056  
12  18  18.14  100.77 ± 0.044  
**Average of six determinations. 
Table: 20: Determination of Precision results for Naproxen at 310 nm by First order derivative Spectroscopy 
Conc.     (µg / 
ml)  
Inter-day  
Absorbance  
Mean ± SD**  
% CV  
Intra-day  
Absorbance  
Mean ± SD**  
% CV  
3  0.0428 ± 0.001169  2.72  0.0423 ± 0.001211  2.86  
6  0.0888 ± 0.001472  1.65  0.0888 ± 0.001751  1.98  
9  0.1368 ± 0.001722  1.25  0.1363 ± 0.00216  1.58  
12  0.1835 ± 0.001871  1.01  0.1836 ± 0.00216  1.17  
15  0.2333 ± 0.002066  0.88  0.2333 ± 0.001966  0.84  
18     0.2741 ± 0.002366  0.86  0.2738 ± 0.002408  0.87  
21     0.3236 ±  0.00216  0.66  0.3241 ± 0.002317  0.71  
24     0.3645 ± 0.002074  0.56  0.3656 ± 0.002338  0.63  
**Average of Six determinations 
          
Figure 5: Calibration curve for Naproxen at 310 nm by First order derivative Spectroscopy 
Table 21: Ruggedness results for Naproxen at 310 nm by First order derivative Spectroscopy 
Brand 
used 
Label claim 
(mg/ml) 
Analyst I Analyst II 
Amount found** 
(mg/ml) 
% Recovery ± 
SD** 
Amount found** 
(mg/ml) 
% Recovery ± SD** 
 
Aleve 20 20.20 102.16 ± 0.0544 20.25 101.58 ± 0.0848 
Naprosyn 20 20.91 99.40 ± 0.0581 20.11 100.73 ± 0.0728 
**Average of six determinations.  
Method C: Second Order Derivative Spectroscopy 
 
Figure 6: Second order derivative spectra of Naproxen at 
353 nm 
Table 22:  Results of calibration curve at 278 nm for 
Naproxen by Second order derivative Spectroscopy 
S. 
No.  
Conc.  
(µg / ml)  
Absorbance   
1  0  0  
2  3  0.007  
3  6  0.015  
4  9  0.023  
5  12  0.031  
6  15  0.039  
7  18  0.047  
8  21  0.054  
9  24  0.062  
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Table 23: Optimum conditions, Optical characteristics and Statistical data of the Regression equation in Second order 
derivative Spectroscopy  
Parameter  UV method  
λ max (nm)  354 
Beer’s law limits (µg / ml)  3-24  
Molar extinction coefficient (L mol-1 cm-1)  0.0026 X 104  
Sandell’s sensitivity  
(µg / cm2 - 0.001 absorbance units)   
0.3846  
Regression equation (Y*)  Y = 0.0026 x – 0.0004  
Slope (b)  0.00026  
Intercept (a)  -0.0004  
Correlation coefficient(r2)  0.9998  
Intraday Precision (% RSD**)  
Interday Precision (% RSD**)  
1.422  
1.460  
Limit of detection (µg / ml)  0.575  
Limit of quantitation (µg / ml)  1.743  
    *Y = bx + a where x is the concentration of Naproxen in µg / ml and Y is the absorbance at the respective λ max.  
    **Average of Six determinations.  
Table: 24-Determination of Accuracy results of Naproxen by Second order derivative Spectroscopy  
Brand used  Amount  
of sample  
(µg / ml)  
Amount of 
drug added  
(µg / ml)  
Amount 
Recovered  
% Recovery ±  
SD**  
Avele 
8  12  12.18     101.5 ± 0.071  
8  15  15.31  102.06 ± 0.06  
8  18  17.93      99.61 ± 0.045  
Naprosyn  
12  12  11.96      99.55 ± 0.591  
12  15  14.88       99.66 ± 0.042  
12  18  18.22    101.22 ± 0.068  
**Average of six determinations. 
Table: 25- Determination of Precision results for Naproxen at 354 nm by Second order derivative Spectroscopy 
Conc.     (µg / 
ml)  
Inter-day  
Absorbance  
Mean ± SD**  
% CV  
Intra-day  
Absorbance  
Mean ± SD**  
% CV  
3  0.0068 ± 0.000408  5.97  0.0071 ± 0.000408     5.69  
6  0.0156 ± 0.000516  3.29  0.0146 ± 0.000516  3.52  
9  0.0223 ± 0.000516  2.31  0.0230 ± 0.000632  2.74  
12  0.0321 ± 0.000753  2.34  0.0315 ± 0.000548  1.73  
15  0.0375 ± 0.000548  1.46  0.0385 ± 0.000548  1.42  
18     0.0451 ± 0.000753  1.66  0.0455 ± 0.000548  1.20  
21     0.0525 ±  0.000837  1.59  0.0538 ± 0.000753  1.39  
24     0.0630 ± 0.000894  1.41  0.0618 ± 0.000751  1.21  
**Average of Six determinations 
        
                                                 Figure 7: Calibration curve for Naproxen at 354 nm by Second order derivative Spectroscopy 
Table: 26- Ruggedness results for Naproxen at 354 nm by Second order derivative Spectroscopy 
Brand used  Label 
claim 
(mg/ml) 
Analyst I Analyst II 
Amount found** 
(mg/ml) 
% Recovery ± 
SD** 
Amount found** 
(mg/ml) 
% Recovery ± 
SD** 
Aleve 20  20.26  102.01 ± 0.0679  20.14  101.14 ± 0.0563  
Naprosyn  20  20.98  99.86 ± 0.0146  20.17  101.13 ± 0.1381  
**Average of six determinations. 
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CONCLUSION 
From the above discussion it can be concluded that the 
proposed method is specific, precise, accurate, linearand 
robust. Results are in good agreement with labelclaim which 
indicates there is no interference of excipients. Therefore the 
proposed method can be used for routine analysis of 
Naproxen in drug substances and formulation. 
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